Celltrion, Inc., founded in 2002, is a leading biopharmaceutical company based in Incheon, South Korea. Specializing in the development, manufacturing, and marketing of biosimilars and innovative biologics, Celltrion's key products include Remsima (infliximab), a biosimilar for autoimmune diseases, and Truxima (rituximab), a biosimilar for non-Hodgkin's lymphoma. In 2023, Celltrion reported revenues of approximately $2 billion. The company is heavily invested in R&D, focusing on the development of new biosimilars and novel biologic drugs. Celltrion collaborates with global pharmaceutical firms to enhance its research capabilities and market reach, maintaining a strong commitment to providing affordable and effective treatments for patients worldwide.

Biosimilar Development: Celltrion has developed a robust platform for developing high-quality biosimilars. Protein Engineering: Modifying proteins to improve their stability, efficacy, and manufacturability. Cell Culture: Optimizing cell culture processes to produce large quantities of biopharmaceuticals. Purification: Developing highly efficient purification processes to isolate and purify the desired biomolecules. Original Biopharmaceutical Development: Beyond biosimilars, Celltrion has also invested heavily in the development of original biopharmaceuticals. This involves: Antibody Engineering: Creating novel antibodies with improved therapeutic properties. Fusion Protein Technology: Developing fusion proteins that combine the properties of different proteins. Manufacturing Capabilities: Celltrion has world-class manufacturing facilities capable of producing large-scale quantities of biopharmaceuticals. These facilities adhere to stringent quality standards and regulatory requirements. Clinical Development: The company has a strong track record in conducting global clinical trials to demonstrate the safety and efficacy of its products.

Public

Investor, CDMO, Bio